ABSTRACT

Diffuse panbronchiolitis (DPB) is a chronic progressive obstructive disease of the airways. Of unknown aetiology, it is responsive to macrolide therapy. Although not uncommon among the Japanese, it is rare in other parts of the world. We report a case of DPB in a Chinese patient in Singapore.

Keywords: diffuse panbronchiolitis, macrolides, Chinese

INTRODUCTION

Diffuse panbronchiolitis (DPB) is an idiopathic chronic obstructive airways disease first reported in 1969 by Japanese workers (1-4). Pathologically it is characterised by infiltration of the bronchiolar wall by lymphocytes and plasma cells with peribronchiolar accumulation of distinctive foamy macrophages. The clinical features include a chronic cough with purulent sputum, wheezing and progressive respiratory failure and death. The poor prognosis has since 1985 been altered by prolonged treatment with low dose erythromycin (5,6) with improvement in the clinical symptoms and the return of respiratory functions to normal.

The disease has been described primarily in the Japanese with occasional cases reported in the other races. Tsang et al (7) report their experience with DPB in seven Chinese patients and in their review of the literature of DPB in non-Japanese subjects found a total of 19 Mongoloid (14 Chinese and 5 Koreans) and 13 non-Mongoloid cases. Recently, however, Park et al (8) stated that the disease is not rare in Koreans, with about 50 cases reported since 1992.

We report a case of DPB in a Chinese patient in Singapore.

CASE REPORT

A 49-year-old Chinese presented in July 1996 with a three-year history of a cough productive of some yellowish green sputum. There was no associated dyspnoea nor wheezing. He had diabetes mellitus for the past three years and also suffered from sinusitis for the past 30 years. He used to smoke but stopped the habit 25 years ago. He was born in Singapore and had no other significant history except his older brother was treated for pulmonary tuberculosis 20 years ago.

Clinically he was well. There were no abnormal findings except for crepitations over the right upper lobe. The chest radiograph revealed some opacities in the right mid-zone and diffuse bibasilar nodules (Fig. 1). His sputum smear for tubercle bacilli was positive with the culture subsequently showing organisms sensitive to the standard anti-tuberculosis drugs. His tuberculosis improved with short course anti-tuberculosis chemotherapy which was stopped in January 1997. However, he continued to have a productive cough and occasional rhonchi were heard over his chest. The basal nodular opacities persisted on his chest radiograph. DPB was suspected and further investigations were done. Respiratory function tests showed airways obstruction with no significant response to aerosol bronchodilator. The diffusing capacity was
normal (Table I). Hypoxemia was present at rest (PaO₂ = 76 mmHg). The blood counts were normal. Culture of his sputum showed no growth of pathogens. His serum immunoglobulins revealed a raised IgA 6.95 G/L (0.7-3.76) and a slightly raised IgG 17.0 G/L (7.30-15.36). Cold agglutinins were negative with negative Mycoplasma pneumoniae titres. Anti-nuclear antibody was negative. The rheumatoid factor was positive.

Blood human leucocyte antigen (HLA) showed the presence of HLA-A 2 and HLA-DR 9 but was negative for Bw 54. Radiographs of his sinuses revealed bilateral maxillary and frontal sinusitis. A thoracic high resolution computed tomograph (HRCT) demonstrated diffuse bronchiolar disease which were predominantly in the lower lobes accompanied by bronchiolar thickening and mild cylindrical bronchiectasis. The small centrilobular nodules were connected to small linear branching densities giving a “tree-in-bud” appearance typical of DPB. The patient declined a lung biopsy.

He was started on erythromycin therapy (500 mg daily). He experienced significant improvement soon after. He became asymptomatic; his chest was clear on repeated physical examination. Eighteen months later, his FEV₁ had returned to normal although he still had some hyperinflation. His IgA and IgG decreased but still remained raised (IgA 5.89 G/L and IgG 15.3 G/L). A thoracic HRCT done two years after the start of erythromycin therapy showed marked improvement. The radiographic findings pre- and post-treatment are shown in Figs. 2 and 3 respectively. An attempt was made at scoring pre- and post-treatment (Table II) as described by Akira et al. and Tsang et al.

<table>
<thead>
<tr>
<th>Table I. Respiratory function tests</th>
<th>Nov 1996</th>
<th>June 1998</th>
<th>Predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁</td>
<td>2.25</td>
<td>2.95</td>
<td>2.93 L</td>
</tr>
<tr>
<td>FVC</td>
<td>3.02</td>
<td>3.88</td>
<td>3.49 L</td>
</tr>
<tr>
<td>FEV₁/FVC %</td>
<td>75</td>
<td>76</td>
<td>84</td>
</tr>
<tr>
<td>MMFR</td>
<td>1.73</td>
<td>2.37</td>
<td>3.44 L/sec</td>
</tr>
<tr>
<td>FRC</td>
<td>3.41</td>
<td>3.00</td>
<td>2.40 L</td>
</tr>
<tr>
<td>RV</td>
<td>2.71</td>
<td>2.42</td>
<td>1.54 L</td>
</tr>
<tr>
<td>TLC</td>
<td>5.71</td>
<td>6.40</td>
<td>5.29 L</td>
</tr>
<tr>
<td>DlCO</td>
<td>9.20</td>
<td>9.20</td>
<td>9.60 ml/min/mmHg</td>
</tr>
</tbody>
</table>

Fig. 2a-b (a) HRCT showing the typical tree-in-bud (Akira type 2) appearance of dilated centrilobular bronchioles filled with pus, fluid or infiltrate in the periphery of the lung. There is also dilatation and thickening of the bronchi. (b) Magnified view.

Fig. 3a-b (a) Complete resolution of the tree-in-bud appearance. The dilated and thickened bronchi have also returned to normal. (b) Magnified view.

Downloadable PDF and full text are available at the journal's website for further reading and research purposes.
Table II. Radiological Assessment.

<table>
<thead>
<tr>
<th></th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akira HRCT grading</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Nodular profusion</td>
<td>1.3</td>
<td>0.8</td>
</tr>
<tr>
<td>Airway dilatation</td>
<td>1.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Airway thickening</td>
<td>1.3</td>
<td>0.7</td>
</tr>
<tr>
<td>Hypo-attenuation</td>
<td>Not significant</td>
<td>Not significant</td>
</tr>
<tr>
<td>Air trapping</td>
<td>Not tested</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

Table III. Clinical diagnostic features of diffuse panbronchiolitis.

Symptoms and signs
- Chronic cough, sputum production, exertional dyspnoea.
- Chronic sinusitis.

Pulmonary function
- Progressive obstructive or mixed restrictive obstructive airways disease.
- Diffusing capacity normal or low.

Radiology
- Diffuse nodular opacities especially lower zones.
- Hyperinflation.
- HRCT demonstrating centrilobular nodules, thickened and ectatic bronchioles and peripheral air trapping.

Laboratory
- No specific diagnostic features.
- Increased serum cold agglutinin without raised anti-Mycoplasma pneumoniae antibody.
- Increased serum IgA and IgG.
- Presence of rheumatoid factor or antinuclear antibodies.
- Sputum cultures positive for H. influenzae or P. aeroginosa.
- HLA-Bw 54 common in Japanese patients.

DISCUSSION

Although histological confirmation is lacking, the typical clinical picture, physiologic and serological findings and plain radiographic chest and thoracic HRCT features meet the diagnostic criteria for DPB outlined in Table III(10). In addition, the response to treatment with erythromycin would confirm the diagnosis.

The lung function results showing an obstructive pattern and a normal diffusing capacity are consistent with those commonly observed in such patients. Unlike Tsang et al(7) who reported a negative rheumatoid factor in all their patients, our patient had a strongly positive rheumatoid factor.

The role of genetic and environmental factors in the pathogenesis of DPB is uncertain. A number of familial cases have been reported in Japan(11) and an association between HLA-Bw 54 and DPB was reported by Sugiyama et al(12) who showed that 63% of patients possessed the Bw 54 antigen compared with 11% of control subjects. This was confirmed by K echness et al(13) although in their study of 76 patients. The frequency of the Bw 54 antigen was relatively lower that the 63% reported previously. This HLA haplotype was, however, not present in the seven Chinese patients reported by Tsang et al(7) who found HLA-A2 and HLA-DR9 in most of their patients. Interestingly, our patient also tested positive for both HLA-A2 and HLA-DR9, but not for Bw 54. A th allele frequency of Bw 54 is highest and similar among Jap anese and Koreans (antigen frequency of 12.2% and 12.6% respectively) and lower in Chinese and other Mongoloids(14,15), a similar HLA association in K orean patients with DPB could be expected if the HLA- Bw 54 antigen is involved in susceptibility to the disease. However, Park et al(16) in their study of 30 Korean patients found the strongest positive association was with HLA-A11. They postulated that “the association of HLA antigens with DPB represent linkage disequilibria to the same disease gene(s) even if different HLA antigens are identified as risk factors in different ethnic groups”, and that HLA class I genes are associated with DPB in both K oreans and J apanese.

Macrolides have been shown to be effective therapy in DPB although the precise mechanism is unknown. A nti-inflammatory actions rather than antimicrobial have been implicated including the reduction of pulmonary levels of pro-inflammatory cytokines IL8, TNFα and leukotriene B4, a potent neutrophil chemoattractant(15,16). Prior to the report of the efficacy of erythromycin by K udoh et al in 1984(17), DPB was associated with a poor prognosis. In a recent retrospective study on the survival of patients treated with low dose erythromycin, K udoh et al(17) report a significant difference in the survival rates between patients treated with erythromycin and those in the nontreated group.

DP5 has to be considered in the differential diagnosis of chronic bronchitis and emphysema, bronchiectasis, primary ciliary dyskinesia, cystic fibrosis and Wegener’s granulomatosis. However, the clinical features, lung function abnormalities and bilateral nodular opacities on the chest radiograph should alert the physician to the diagnosis.

REFERENCES